ClinicalTrials.gg
RecruitingNCT04482374Updated Jun 10, 2025

Puberty Suppression and Cardiometabolic Health

An observational study in Transgenderism, Insulin Sensitivity/Resistance and Endothelial Dysfunction, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to male participants aged 9 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Primary conditionTranssexualism(the registry's first term)UnverifiedIs this wrong?Transsexualism is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
9 Years to 14 Years
Sex
Male
01

Study summary

This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.

02

Conditions studied

  • Transgenderism
  • Insulin Sensitivity/Resistance
  • Endothelial Dysfunction
  • Vascular Stiffness

Browse trials for

03

In context

Transsexualism Unverified

54 studies on the registry are indexed under Transsexualism; 18 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 28 observational studies indexed under Transsexualism.

Browse Transsexualism studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.

Compared within Transsexualism, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
9 Years to 14 Years
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

15 transgender females (male sex assigned at birth, female gender identity) and 15 cisgender males

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Identify as a transgender female or cisgender male
  • Age 9-14 years at the time of enrollment
  • Tanner Stage 2-3 baseline pubertal development
  • Plan to start gonadotropin releasing hormone analogue clinically in \< 2 months (for transgender females only)

Exclusion criteria

Exclusion Criteria:

  • Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
  • Type 1 or 2 diabetes (by medical history)
  • On any medications that affect insulin sensitivity (e.g. metformin, antipsychotics)
  • Hypertension (resting BP ≥ 140/90 mm/Hg)
  • Weight > 400 lbs
  • On estrogen- or progesterone-containing medications at baseline
  • >3 hours of moderate-to-vigorous physical activity on the 3DPAR at the screening visit
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Transgender females

    Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months

  • Cisgender males

    Cisgender male controls

06

What researchers measure

Primary outcomes

  1. Change in insulin sensitivity

    Insulin sensitivity assessed by the oral minimal model

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Change in body composition (fat mass, fat-free mass)

    Body composition measured by DXA

    Time frame: Baseline, 6 months

  2. Change in resting metabolic rate

    Resting metabolic rate assessed by indirect calorimetry

    Time frame: Baseline, 6 months

  3. Change in endothelial function

    Endothelial function assessed by brachial artery flow mediated dilation

    Time frame: Baseline, 6 months

  4. Change in large elastic artery stiffness

    Large elastic assessed by carotid ultrasound

    Time frame: Baseline, 6 months

  5. Change in cerebrovascular function

    Middle cerebral artery blood flow assessed using bilateral transcranial Doppler

    Time frame: Baseline, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Jul 2026, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 22, 2020
StartActual
Aug 10, 2020
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04482374
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Aug 10, 2020
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Jun 10, 2025

Study contacts

Natalie J Nokoff, MD, MSCS
Contact
natalie.nokoff@childrenscolorado.org
720-777-6128
Natalie J Nokoff, MD, MSCS
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion